Amir Qaseem

This article summarizes the ACP/Annals Forum held on 14 October 2026.

This article summarizes the American College of Physicians (ACP) clinical guidelines on pharmacologic treatments for perimenopausal and postmenopausal females experiencing vasomotor symptoms. Devel... Description: The American College of Physicians (ACP) developed this clinical guideline on pharmacologic treatments for internal medicine physicians and other clinicians caring in outpatient settin...

Migraine is a chronic condition that affects about 15% of the population in the United States and is characterized by recurrent, debilitating headache that lasts somewhere between 4 and 72 hours. Only 1 performance measure for migraine is currently in use in pay-for-performance programs. Although the American College of Physicians (ACP) broadly supports the role of performance measurement in performance improvement, this support is based on the principle that only measures that are evidence-based and meet high standards of methodological soundness are appropriate given their potential impact on patient care. ACP's Performance Measurement Committee reviews performance measures using a rigorous process to recognize high-quality performance measures, address gaps and areas for improvement in performance measures, and help reduce reporting burden. This article presents a review of 1 performance measure that includes migraine and considers a potential core performance measure using ACP's process to inform physicians, payers, and policymakers.

The purpose of this updated guidance statement is to guide internal medicine physicians and other clinicians on screening for breast cancer in asymptomatic, average-risk adult females. The American College of Physicians updated its guidance statement on screening for breast cancer using high-quality clinical guidelines from national guideline developers around the world. In asymptomatic, average-risk females aged 40 to 49 years, clinicians should discuss the female's risk of breast cancer, values and preferences, and uncertainty around benefits and harms of screening for breast cancer. Following shared decision making, if a female in this population prefers to get screened for breast cancer, clinicians should then initiate screening mammography every 2 years (biennial). In asymptomatic, average-risk females aged 50 to 74 years, clinicians should use biennial mammography for screening for breast cancer. In asymptomatic, average-risk females aged 75 years or older or asymptomatic, average-risk females with a limited life expectancy, clinicians should discuss discontinuation of breast cancer screening based on shared decision making that includes the female's risk of breast cancer, values and preferences, and uncertainty around benefits and harms of screening for breast cancer. In asymptomatic, average-risk adult females with breast density of Breast Imaging Reporting and Data System (BI-RADS) category C or D, clinicians should consider using supplemental digital breast tomosynthesis based on benefits, harms, additional radiation exposure, availability, values and preferences, and cost. In asymptomatic, average-risk adult females with breast density of BI-RADS category C or D, clinicians should not use supplemental magnetic resonance imaging or ultrasound.

This article summarizes the ACP/Annals Forum held on 11 March 2026.